Impact of VEGF expression on pembrolizumab outcomes in mNSCLC

Real-world analysis identifying high VEGF expression as a driver of immunotherapy resistance

INDICATION
Lung
BIOMARKER
VEGF

 

rwOS with risk-set adjustment  anchored on 1L start date in patients receiving 1L pembrolizumab treatment stratified based on VEGF expression (mean of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PGF). (Time = Months).

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Grid displaying data points with blue, black, and gray squares on a white background.

RB1 loss-of-function mutations in post-Osimertinib NSCLC and prognostic implications

2026-07-01
Lung
RB1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of small blue, gray, black, and orange squares on a white background.

Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma

2026-07-01
Lung
PPM1D
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Pixelated diagonal gradient with bands of purple, blue, and green dots, resembling data visualization.

PRAME expression and histology impact survival in first-line NSCLC

2026-05-26
Lung
PRAME